NEONeogenomics Inc.
$14.14
$0.025
(0.18%)
EarningsJul 28
Mkt Cap$1.84B
Vol862,889.00
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) for patients with...
Business Wire
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. Company management will host a...
Business Wire
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors. Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and...
Business Wire
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate principal amount of 0.75% convertible senior notes due 2032 (the notes) to persons...
Business Wire
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the notes) to persons reasonably believed to...
Business Wire
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it will showcase eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29June 2, 2026, in Chicago (booth #32130...
Business Wire
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences...
Business Wire
TD Cowen Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price
TD Cowen boosted their target price on shares of NeoGenomics from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat
<
1
2
...
>